Olema Pharmaceuticals マネジメント

マネジメント基準チェック /34

Olema Pharmaceuticalsの CEO はSean Bohenで、 Sep2020年に任命され、の在任期間は 4.17年です。の年間総報酬は$ 3.15Mで、 20.5%給与と79.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.25%を直接所有しており、その価値は$ 1.47M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と4.3年です。

主要情報

Sean Bohen

最高経営責任者

US$3.2m

報酬総額

CEO給与比率	20.5%
CEO在任期間	4.2yrs
CEOの所有権	0.3%
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Aug 29

Olema Pharmaceuticals: Still Merits A Small Holding

Jun 17

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

May 11

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Mar 28

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19

CEO報酬分析

Olema Pharmaceuticals の収益と比較して、Sean Bohen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$123m
Jun 30 2024	n/a	n/a	-US$110m
Mar 31 2024	n/a	n/a	-US$99m
Dec 31 2023	US$3m	US$647k	-US$97m
Sep 30 2023	n/a	n/a	-US$96m
Jun 30 2023	n/a	n/a	-US$97m
Mar 31 2023	n/a	n/a	-US$110m
Dec 31 2022	US$6m	US$616k	-US$105m
Sep 30 2022	n/a	n/a	-US$100m
Jun 30 2022	n/a	n/a	-US$95m
Mar 31 2022	n/a	n/a	-US$79m
Dec 31 2021	US$3m	US$595k	-US$71m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$52m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$11m	US$178k	-US$24m

報酬と市場: Seanの総報酬 ($USD 3.15M ) は、 US市場 ($USD 2.12M ) の同規模の企業の平均を上回っています。

報酬と収益: Seanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sean Bohen (57 yo)

4.2yrs

在職期間

US$3,152,370

報酬

Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sean Bohen	President	4.2yrs	US$3.15m	0.25% $ 1.5m
Shane William Kovacs	Chief Operating & Financial Officer	4.4yrs	US$1.55m	0.89% $ 5.2m
Naseem Zojwalla	Chief Medical Officer	2.8yrs	US$1.30m	0.16% $ 909.0k
Courtney O'Konek	Vice President of Corporate Communications	less than a year	データなし	データなし
Julie Dexter	Senior VP & Head of People	no data	データなし	データなし
David Myles	Chief Discovery & Non-Clinical Development Officer	4.4yrs	US$200.00k	1.3% $ 7.5m
Sasha Austin	VP of Finance & Controller	1.8yrs	データなし	データなし

3.5yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: OLMAの経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sean Bohen	President	4.2yrs	US$3.15m	0.25% $ 1.5m
Andrew Rappaport	Independent Director	11.8yrs	US$176.65k	0.67% $ 3.9m
Cynthia Butitta	Independent Director	4.3yrs	US$180.15k	0.15% $ 848.8k
Ian T. Clark	Independent Chairperson of the Board	4.3yrs	US$198.65k	0% $ 0
Frank McCormick	Chairman of Scientific Advisory Board	3.6yrs	US$11.81k	データなし
Pamela M. Klein	Member of Scientific Advisory Board	no data	データなし	データなし
Sandra Horning	Independent Director	4yrs	US$158.15k	0% $ 0
Scott Garland	Independent Director	1.1yrs	US$280.21k	0% $ 0
Graham L. Walmsley	Independent Director	4.7yrs	US$171.15k	0% $ 0
Yi Larson	Independent Director	3.6yrs	US$163.15k	0% $ 0
Gorjan Hrustanovic	Independent Director	6.3yrs	US$165.15k	0% $ 0
Cyrus Harmon	Director	18.3yrs	US$1.33m	1.53% $ 8.8m

4.3yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: OLMAの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Olema Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Chief Operating & Financial Officer exercised options to buy US$207k worth of stock.

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Insufficient new directors

Olema Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Recent updates

Chief Operating & Financial Officer exercised options to buy US$207k worth of stock.

New major risk - Revenue and earnings growth

Olema Oncology Announces New Preclinical Combination Data to Be Presented At the 2024 Eortc-Nci-Aacr Symposium on Molecular Targets and Cancer Therapeutics

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

Director notifies of intention to sell stock

Olema Pharmaceuticals: Still Merits A Small Holding

Director notifies of intention to sell stock

Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Director notifies of intention to sell stock

Insufficient new directors

Olema Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Director notifies of intention to sell stock

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Director notifies of intention to sell stock

Chief Medical Officer exercised options to buy US$241k worth of stock.

Chief Operating & Financial Officer exercised options to buy US$563k worth of stock.

Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies

President recently sold US$824k worth of stock

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Director notifies of intention to sell stock

Price target increased by 13% to US$24.43

Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Olema Pharmaceuticals, Inc. Appoints Scott Garland to Its Board of Directors

Olema Pharmaceuticals, Inc. Announces Phase 2 Monotherapy Clinical Results to Be Presented At the 2023 Esmo Congress

Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Olema Pharmaceuticals, Inc. announced that it has received $129.999989 million in funding

Olema Pharmaceuticals, Inc. announced that it expects to receive $129.999989 million in funding

Olema Pharmaceuticals, Inc. announced that it expects to receive $129.999989 million in funding

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Corporate Secretary notifies of intention to sell stock

Corporate Secretary notifies of intention to sell stock

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Director recently sold US$63k worth of stock

Corporate Secretary notifies of intention to sell stock

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1B/2 Study

Price target increased by 12% to US$15.00

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Pharmaceuticals, Inc. Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study

Price target decreased to US$14.50

High number of new and inexperienced directors

Olema Pharmaceuticals, Inc. Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

Olema Oncology grants stock options for 58.3K shares

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) dropped from Russell 2000 Growth Index

Olema Pharmaceuticals, Inc. Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program

Price target decreased to US$26.20

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Price target decreased to US$30.75

High number of new and inexperienced directors

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Olema Pharmaceuticals, Inc. Announces Management Changes

Our Take On Olema Pharmaceuticals

Chief Development Officer recently sold US$103k worth of stock

Price target decreased to US$46.25

Olema Pharmaceuticals, Inc. Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer

マネジメント基準チェック /34